In spite of its higher antiproliferative potential compared to IFN-α, the clinical use of IFN-β in cancer therapy has been limited by its low bioavailability and sustained side effects; however, this may be overcome by delivery in different routes and schedules. Here, IFNA1 is linked to cancer.